The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Open accessAbstract
BACKGROUND: High plasma levels of nonfasting triglycerides are associated with an increased risk of ischemic cardiovascular disease. Whether lifelong low levels of nonfasting triglycerides owing to mutations in the gene encoding apolipoprotein C3 (APOC3) are associated with a reduced risk of ischemic cardiovascular disease in the general population is unknown. METHODS: Using data from 75,725 participants in two general-population studies, we first tested whether low levels of nonfasting triglycerides were associated with reduced risks of ischemic vascular disease and ischemic heart disease. Second, we tested whether loss-of-function mutations in APOC3, which were associated with reduced levels of nonfasting triglycerides, were also associated with reduced risks of ischemic vascular disease and ischemic heart disease. During follow-up, ischemic vascular disease developed in 10,797 participants, and ischemic heart disease developed in 7557 of these 10,797 participants. RESULTS: Participants with nonfasting triglyceride levels of less than 1.00 mmol per liter (90 mg per deciliter) had a significantly lower incidence of cardiovascular disease than those with levels of 4.00 mmol per liter (350 mg per deciliter) or more (hazard ratio for ischemic vascular disease, 0.43; 95% confidence interval [CI], 0.35 to 0.54; hazard ratio for ischemic heart disease, 0.40; 95% CI, 0.31 to 0.52). Heterozygosity for loss-of-function mutations in APOC3, as compared with no APOC3 mutations, was associated with a mean reduction in nonfasting triglyceride levels of 44% (P<0.001). The cumulative incidences of ischemic vascular disease and ischemic heart disease were reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, respectively), with corresponding risk reductions of 41% (hazard ratio, 0.59; 95% CI, 0.41 to 0.86; P=0.007) and 36% (hazard ratio, 0.64; 95% CI, 0.41 to 0.99; P=0.04). CONCLUSIONS: Loss-of-function mutations in APOC3 were associated with low levels of triglycerides and a reduced risk of ischemic cardiovascular disease. (Funded by the European Union and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss-of-function variants in APOC3 confer protection against coronary artery disease, independent of LDL cholesterol levels [60, 112]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease.[9][10][11][12][13]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrary, loss-of-function mutations of the ApoC-III are associated with a lower risk of CVD [170–172].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [171]
The cited source says what the claim attributes to it.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Low-density lipoprotein (LDL) cholesterol and triglyceride-rich remnant lipoproteins are causally associated with risk of atherosclerotic vascular disease [3][4][5][6]”
From APOE and vascular disease: Sequencing and genotyping in general population cohorts (2023) · cites this paper as [4]
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“ApoCIII is a predictor of CV disease and reduced apoCIII levels may have direct beneficial effects on the vessel wall, such as by reducing its retention of LDL particles (LDL-apoCIII) [48–50].”
In the citing paper
“Some rare heterozygous loss-of-function (LOF) variants are associated with reduced TG levels. These patients show protection from ASCVD providing important evidence for a causal role of TG for ASCVD.”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“Such LOF variants of APOC3 are also associated with reduced ASCVD risk.10”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [10]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD. 106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Recent data from genetic studies utilizing a Mendelian randomization design have consistently linked both non-fasting TG levels as well as remnant cholesterol to increased risk of CVD events and all-cause mortality.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Furthermore, loss of function mutations are associated with low TGs as well as with reduced risk for CVD.106,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“Recent data from genetic studies utilizing a Mendelian randomization design have consistently linked both non-fasting TG levels as well as remnant cholesterol to increased risk of CVD events and all-cause mortality.86,107”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [107]
In the citing paper
“defects in genes controlling TG metabolism, including APOC3, ANGPTL3 and ANGPTL4 that have been linked to reduced TG and are associated with reduced coronary calcification25 or reduced CVD risk.26-30”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Pre-mRNA splicing and human diseasePreprint
Faustino, N. A., & Cooper, T. A. (2003) · Genes & Development · doi:10.1101/gad.1048803 · Cited by 1,248
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationRemnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Self-citation
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Cited by
Sorted by citations
Items 601–700 of 923
A statistical physics approach for disease module detectionPreprint
Wang, X., Qiao, D., Cho, M. H., DeMeo, D. L., Silverman, E. K., & Liu, Y. (2022) · Genome Research · doi:10.1101/gr.276690.122 · Cited by 7
Ference, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
Genetics of remnant cholesterol
Wulff, A. B., & Nordestgaard, B. G. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000991 · Cited by 8
Self-citationApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?
Biolo, M., Galimberti, F., Portinari, C., Bertocco, S., Tosin, P., Casula, M., Previato, L., Zambon, S., Simioni, P., & Zambon, A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01315-w · Cited by 9
ω-3 carboxylic acids for hypertriglyceridemia
Roth, E. M. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.991307 · Cited by 8
Genetics for the Identification of Lipid Targets Beyond PCSK9
Wang, L. R., & Hegele, R. A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.11.003 · Cited by 8
Chen, R. K., Petrazzini, B. O., Duffy, Á., Rocheleau, G., Jordan, D. M., Bansal, M. B., & Do, R. (2025) · Genome biology · doi:10.1186/s13059-025-03518-5 · Cited by 10
Resurgence of targets and compounds to treat dyslipidaemia
Kastelein, J. J. P. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.132 · Cited by 8
Sinning, D., Leistner, D. M., & Landmesser, U. (2016) · Herz · doi:10.1007/s00059-016-4430-8 · Cited by 9
Crandell, J. R., Tartaglia, C., & Tartaglia, J. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1241129 · Cited by 8
Thaane, T., Motala, A. A., & McKune, A. J. (2018) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000816 · Cited by 7
Uncovering the role of apolipoprotein C-III in insulin resistance
Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.09.003 · Cited by 8
Apolipoprotein genetic variants and hereditary amyloidosis
Jeraj, N., Hegele, R. A., & Berberich, A. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000736 · Cited by 8
Approach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 8
Sex‐Specific Parental Effects on Offspring Lipid Levels
Predazzi, I. M., Sobota, R. S., Sanna, S., Bush, W. S., Bartlett, J., Lilley, J. S., Linton, M. F., Schlessinger, D., Cucca, F., Fazio, S., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.001951 · Cited by 8
Genetic variation in WRN and ischemic stroke: General population studies and meta-analyses
Christoffersen, M., Frikke‐Schmidt, R., Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.01.005 · Cited by 8
Self-citationJo, G., Kwak, S., Kim, J. Y., Lim, H., & Shin, M. (2018) · Nutrients · doi:10.3390/nu10111595 · Cited by 9
Pedro‐Botet, J., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., Hernández‐Mijares, A., Pintó, X., & Millán, J. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.12.003 · Cited by 14
Experimental Biology for the Identification of Causal Pathways in Atherosclerosis
Guo, Y., Garcia-Barrio, M. T., Wang, L., & Chen, Y. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6644-7 · Cited by 8
Raadsen, R., Dijkshoorn, B., van Boheemen, L., ten Boekel, E., van Kuijk, A. W. R., & Nurmohamed, M. T. (2023) · Joint Bone Spine · doi:10.1016/j.jbspin.2023.105683 · Cited by 7
Dimmeler, S., Ferri, L. D. A. F., Nioi, P., O’Donnell, C. J., Damy, T., Gómez‐Outes, A., Giacca, M., Guo, W., Kavousi, M., Kupatt, C., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf041 · Cited by 7
Gene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation
Bezsonov, E. E., Chernyi, N., Saruhanyan, M., Shimchenko, D., Bondar, N., Gavrilova, D., Baig, M. S., & Malogolovkin, A. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146950 · Cited by 8
Yang, X., Alexander, V. J., Xia, S., & Tsimikas, S. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120462 · Cited by 7
Apolipoprotein C-III in patients with systemic lupus erythematosus
Martín‐González, C., Ferrer‐Moure, C., Quevedo-Abeledo, J. C., de Vera-González, A., Delgado, A. G., Sánchez-Martín, J., González-Gay, M. Á., & Ferraz‐Amaro, I. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02793-y · Cited by 7
Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes
Guardiola, M., Rehues, P., Amigó, N., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Girona, J., Martínez‐Montoro, J. I., Ortega, E., Pérez, A., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14214 · Cited by 7
Balling, M., Afzal, S., Varbo, A., Nordestgaard, B. G., & Langsted, A. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae217 · Cited by 10
Self-citationSchwartz, G. G., Szarek, M. J., Reijnders, E., Jukema, J. W., Bhatt, D. L., Bittner, V., Fazio, S., Garon, G., Goodman, S. G., Harrington, R. A., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf067 · Cited by 7
Packard, C. J., Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Andersson, L. K., Adiels, M., & Borén, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119166 · Cited by 7
Clarifying complex inheritance: apolipoprotein C3 and atherosclerosis
Galton, D. J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000425 · Cited by 7
A New Start for Triglycerides and Remnant Cholesterol—Nonfasting
Nordestgaard, B. G. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.268938 · Cited by 7
Self-citationHallén, J., & Sreeharan, N. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy029 · Cited by 7
Young, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Mortensen, M. B., & Nordestgaard, B. G. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.12.002 · Cited by 7
Self-citationHypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment
Wieczorek, E., Ćwiklińska, A., & Jankowski, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0189 · Cited by 7
Cardiovascular risk reduction: the future of cholesterol lowering drugs
Malham, S. B., & Goldberg, A. C. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.01.007 · Cited by 8
Using human genetics to discover new therapeutic targets for plasma lipids
Cohen, J. C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12521 · Cited by 7
Mechanistic insights from combining genomics with metabolomics
Drenos, F. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000393 · Cited by 7
Dedousis, N. L., Teng, L., Kanshana, J. S., & Kohan, A. B. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100284 · Cited by 7
Colesterol-no HDL como objetivo terapéutico
Brea, Á., Hernández‐Mijares, A., Millán, J., Ascaso, J. F., Blasco, M., Rodríguez, Á. D., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.07.002 · Cited by 8
Peng, X., Lian, Z., O’Brien, V., Xiao, J., Litchfield, B., Perrard, X. D., Lu, X., Ni, J., Mukherjee, A., Simmons, T., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100763 · Cited by 7
Ashraf, T., Devi, N., Aradhna, F., Devi, S., Nancy, F., Kumar, A., Ameer, F., Absar, F., Kumar, L., Kumar, S., et al. (2025) · Annals of Medicine & Surgery · doi:10.1097/ms9.0000000000003505 · Cited by 6
Björnson, E., Packard, C. J., Adiels, M., Leeper, N. J., Hellawell, J. L., Gummesson, A., Nissen, S. E., & Borén, J. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf657 · Cited by 6
Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review
Luca, C. D., Ciciola, P., D’Errico, G., Taranto, M. D. D., Fortunato, G., Gross, C., Garn, J., Iannuzzo, G., Minno, M. N. D. D., & Calcaterra, I. L. (2025) · Genes · doi:10.3390/genes16111377 · Cited by 7
Björnson, E., Adiels, M., Taskinen, M., Packard, C. J., & Borén, J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01399-y · Cited by 8
APOC3 mutations lower CVD risk
Geach, T. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.99 · Cited by 6
An up-to-date review of emerging biologic therapies for hypercholesterolemia
Tomlinson, B. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2442455 · Cited by 6
Biswas, A., Arshid, S., Kristensen, K. K., Jørgensen, T. J. D., & Ploug, M. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100745 · Cited by 6
Emerging agents targeting triglycerides
Prakash, Y. S., Bhatt, D. L., & Malick, W. A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000979 · Cited by 7
Gagnon, É., Gill, D., Chabot, D., Cronjé, H. T., Yuan, S., Brennan, S., Thériault, S., Burgess, S., Arsenault, B. J., & Dib, M. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.124.004933 · Cited by 10
Verbeek, R., Oldoni, F., Surendran, R. P., Zwinderman, A. H., Khaw, K., Stroes, E. S. G., Wareham, N. J., Boekholdt, S. M., & Dallinga‐Thie, G. M. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.02.005 · Cited by 6
Life is complicated: so is apoCIII
Reyes‐Soffer, G., & Ginsberg, H. N. (2019) · Journal of Lipid Research · doi:10.1194/jlr.c119000214 · Cited by 6
Dyslipidemia in type 2 diabetes mellitus
Stefanović, A., Zeljković, A., Vekić, J., Spasojević‐Kalimanovska, V., Jelić‐Ivanović, Z., & Spasić, S. (2019) · Arhiv za farmaciju · doi:10.5937/arhfarm1905338s · Cited by 6
Li, H., Lim, D., Chen, M., Ibrahim, J. G., Kim, S., Shah, A. K., & Lin, J. (2021) · Statistics in Medicine · doi:10.1002/sim.8983 · Cited by 7
Cui, H., & Du, Q. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-1592-5_8 · Cited by 6
Kim, D. H., Lee, S., Noh, S. G., Lee, J., & Chung, H. Y. (2024) · Aging · doi:10.18632/aging.205610 · Cited by 6
Joshi, P. H., Miller, P. E., Martin, S. S., Jones, S. R., Massaro, J. M., D’Agostino, R. B., Kulkarni, K. R., Sponseller, C. A., & Toth, P. P. (2017) · AIDS · doi:10.1097/qad.0000000000001423 · Cited by 6
Is it time to abandon fasting for routine lipid testing?
Farukhi, Z. M., & Mora, S. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.16135 · Cited by 6
Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki, K. C., & Dicklin, M. R. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000741 · Cited by 6
Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia
Parthymos, I., Kostapanos, M. S., Liamis, G. L., & Florentin, M. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9020042 · Cited by 6
Apolipoprotein Profiles in Very Preterm and Term‐Born Preschool Children
Posod, A., Pechlaner, R., Yin, X., Burnap, S. A., Zollner-Kiechl, S., Willeit, J., Witztum, J. L., Mayr, M., Kiechl, S. J., & Kiechl‐Kohlendorfer, U. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011199 · Cited by 6
Genetic variants in SUSD2 are associated with the risk of ischemic heart disease
Bruikman, C. S., Dalila, N., van Capelleveen, J. C., Kroon, J., Peter, J., Havik, S. R., Willems, M. C. M., Huisman, L. C., de Boer, O. J., Hovingh, G. K., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.05.100 · Cited by 6
Self-citationThe Potential of RNA Therapeutics in Treating Cardiovascular Disease
Mainkar, G., Ghiringhelli, M., & Zangi, L. (2025) · Drugs · doi:10.1007/s40265-025-02173-1 · Cited by 6
Apolipoproteins in circulation: At the interface of thrombosis and stroke initiation
Etuzé, T., Vivien, D., & Dubois, F. (2025) · Progress in Lipid Research · doi:10.1016/j.plipres.2025.101343 · Cited by 6
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers
Wang, F., You, D., Niu, X., Shi, J. G., Li, Y., Qi, L., & Li, H. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02929-9 · Cited by 5
Cabodevilla, A. G., Izquierdo, M. C., Basu, D., Younis, W., Tirumalasetty, M. B., Miao, Q. R., Nasias, D., Kanter, J. E., Ho, T. W. W., Gjini, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68193-3 · Cited by 5
Björnson, E., Packard, C. J., & Borén, J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109010 · Cited by 6
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering
Gaudet, D., Larouche, M., Raal, F. J., & Catapano, A. L. (2026) · Circulation Research · doi:10.1161/circresaha.126.327270 · Cited by 5
Labordiagnostik von Fettstoffwechselstörungen
März, W., Scharnagl, H., Kleber, M. E., Silbernagel, G., Nauck, M., Müller‐Wieland, D., & von Eckardstein, A. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1516-2511 · Cited by 5
Jeong, J., Rastogi, A., Kim, T., Henry, S. P., Hoffmaster, C. M., Kim, S. Y., Kim, W., Lee, S.-Y., Park, J., Wi, I.-S., et al. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2024.0057 · Cited by 5
Rehues, P., Girona, J., Guardiola, M., Ozcariz, E., Amigó, N., Rosales, R., Esteban, Y., Banús, H., Alsina, G. G., González-Lleó, A. M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02531-5 · Cited by 6
Gagnon, É., Gill, D., Burgess, S., & Arsenault, B. J. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf018 · Cited by 5
Analytic and Translational Genetics
Karczewski, K. J., & Martin, A. R. (2020) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-072018-021148 · Cited by 6
Chukwurah, M. I., & Miller, M. J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01926-2 · Cited by 5
Serum cholesterol as a risk factor for coronary heart disease revisited
Rossouw, J. (2015) · South African Journal of Clinical Nutrition · doi:10.1080/16070658.2015.11734523 · Cited by 5
APOC3: Triglycerides do matter
Hassan, M. S. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.38 · Cited by 5
APOC3 may not be a predictor of risk of ischemic vascular disease in the Chinese population
Tang, L. V., Cheng, Z., Wang, Q., Zeng, W., Liu, H., Wu, Y., Hu, B., & Hu, Y. (2014) · F1000Research · doi:10.12688/f1000research.5676.1 · Cited by 5
Lipids and cardiovascular disease 3 Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · Cited by 5
Self-citationSingle-Particle Tracking of Human Lipoproteins
de Messieres, M., Ng, A., Duarte, C. J., Remaley, A. T., & Lee, J. C. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b03749 · Cited by 5
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
Corbin, L. J., Hughes, D. A., Chetwynd, A. J., Taylor, A. E., Southam, A. D., Jankevics, A., Weber, R. J. M., Groom, A., Dunn, W. B., & Timpson, N. J. (2020) · Metabolomics · doi:10.1007/s11306-020-01689-9 · Cited by 5
Khan, M. S., Ishaq, M., Ayub, M. T., Rehman, A. U., Hayes, J. J., Mortada, M. E., & Biederman, R. W. (2021) · Journal of Lipids · doi:10.1155/2021/6696915 · Cited by 6
Li, J., Zhao, D. H., Liu, J., Wang, M., Sun, J., Liu, J., Li, Y., Deng, Q., & Qi, Y. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-052388 · Cited by 5
Genetically Engineered Hamster Models of Dyslipidemia and Atherosclerosis
Xian, X., Wang, Y., & Liu, G. E. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_26 · Cited by 6
New therapeutic approaches for the treatment of hypertriglyceridemia
Gouni‐Berthold, I., & Schwarz, J. (2022) · Herz · doi:10.1007/s00059-022-05113-x · Cited by 6
Safabakhsh, S., Al-Shaheen, A., Swiggum, E., Mielniczuk, L. M., Tremblay‐Gravel, M., & Laksman, Z. (2022) · CJC Open · doi:10.1016/j.cjco.2022.07.012 · Cited by 6
Baidya, A. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0039 · Cited by 5
Kastelein, J. J. P. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61332-5 · Cited by 5
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 5
Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPLT3
Landmesser, U., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa790 · Cited by 5
Tang, X. L., Hooper, A. J., & Burnett, J. R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2414126 · Cited by 4
Dysregulated Lipid Metabolism as a Central Driver of Atherosclerotic Plaque Pathology
Steinbeck, J. E., Iannotti, R. A., & Rasheed, A. (2025) · Lipidology · doi:10.3390/lipidology2040017 · Cited by 5
Kouvari, M., Valenzuela‐Vallejo, L., Guatibonza-García, V., Verrastro, O., Axarloglou, E., Mylonakis, S. C., George, J., Papatheodoridis, G., Mingrone, G., & Mantzoros, C. S. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.10.007 · Cited by 4
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors
Mansoor, T., Nambi, V., Parikh, S. S., Misra, A., Ismayl, M., Sullivan, C., Sperling, L. S., Virani, S. S., Rifai, M. A., Koshy, S. K. G., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00748-7 · Cited by 4
Erbasan, E., Aliciaslan, M., Erendor, F., Şanlioğlu, A. D., & Şanlıoğlu, S. (2025) · Gene Therapy · doi:10.1038/s41434-025-00575-0 · Cited by 5
Nordestgaard, L. T., Luo, J., Emanuelsson, F., Leyden, G. M., Sanderson, E. C. M., Smith, G. D., Christoffersen, M., Afzal, S., Benn, M., Nordestgaard, B. G., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf662 · Cited by 4
Self-citationAlcover, S., Ramos-Regalado, L., Muñoz‐García, N., Girón, G. O., Otero, S., López, S., Padró, T., Badimón, L., & Vilahur, G. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag187 · Cited by 4
Ginsberg, H. N., & Bornfeldt, K. (2026) · Circulation Research · doi:10.1161/circresaha.125.327267 · Cited by 4
Bahbah, E. I., Shehata, M., Alnahrawi, S. I., Sayed, A., Menshawey, A., Fisal, A., Morsi, M., Gabr, M. E., & Elbasit, M. S. A. (2021) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2021.102282 · Cited by 4
Genome Editing in Dyslipidemia and Atherosclerosis
Chen, Z., Lehertshuber, C., & Schunkert, H. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_10 · Cited by 8
Metadata
- Authors
- Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-03
- Volume
- 371
- Issue
- 1
- Pages
- 32-41
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2052644460
- Semantic Scholar
- 55f5e169d6f4d9a568cca4bbafe0790022e8bc16
- Cited by
- 919
- References
- 39
- Citations by year
- 2026: 50 · 2025: 76 · 2024: 49 · 2023: 46 · 2022: 65 · 2021: 64 · 2020: 95 · 2019: 71 · 2018: 71 · 2017: 99 · 2016: 113 · 2015: 87 · 2014: 32
- FWCI
- 75.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Gentofte Hospital
- Rigshospitalet
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, ischemic vascular disease, ischemic heart disease, cardiovascular risk, heterozygosity, genetic variants, triglyceride lowering, general population, hypertriglyceridemia, genetic epidemiology, Mendelian randomization
- MeSH terms
- Adult, Aged, Female, Genotype, Humans, Ischemia, Cholesterol, LDL, Liver, Male, Middle Aged, Mutation, Risk Factors, Triglycerides, Incidence, Myocardial Ischemia, Sequence Analysis, DNA, Apolipoprotein C-III, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
